Friday, July 10, 2026

Drug profile · INN

ospemifene

ospemifene (SENSHIO) is a estrogen receptor modulator. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved Genito-urinary system and sex hormones (G03) G03XC05
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ospemifene
US status
approved
Class
Genito-urinary system and sex hormones (G03)
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

ospemifene (SENSHIO) is a estrogen receptor modulator. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN ospemifene
Brand SENSHIO
Mechanism Estrogen receptor modulator
Target Estrogen receptor
Therapeutic class Genito-urinary system and sex hormones (G03)
Route ORAL
Formulation TABLET
ATC code G03XC05

Mechanism of action

Estrogen receptor modulator

Primary target: Estrogen receptor

Approval history

Authority Status Date
FDA approved
EMA approved

Related & competitor drugs

  1. apomorphine Genito-urinary system and sex hormones (G04)
  2. estradiol Estrogen receptor alpha agonist
  3. estradiol valerate Estrogen receptor alpha agonist
  4. estrogens, conjugated synthetic a Estrogen receptor agonist
  5. estropipate Estrogen receptor alpha agonist
  6. ethinyl estradiol Estrogen receptor alpha agonist

Frequently asked questions

What is ospemifene?

ospemifene (SENSHIO) is a estrogen receptor modulator. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for ospemifene?

SENSHIO is a marketed brand name for ospemifene. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ospemifene?

ospemifene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.